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Abstract 
Background and Aims: Bariatric surgery results in the remission of type 2 diabetes mellitus 
(T2DM) in morbidly obese subjects. The aim of the study was to investigate the predictive 
value of both static and dynamic measures of C-peptide in relation to T2DM resolution 6 
months after bariatric surgery regardless of the operation type. 
Methods and Results: A non-randomized prospective study of 24 participants with T2DM 
undergoing bariatric surgery. Measurements of fasting and 2-hour plasma glucose, insulin, C-
peptide and measures of insulin sensitivity were recorded temporally during an oral glucose 
tolerance test pre-operatively and 6 months post-operatively. A responder was defined with a 
fasting glucose <5.6mmol/L and HBA1c <6.0% postoperatively. Within the sample there were 
11 responders and 13 non-responders at 6 months. There was a significant difference in the 
duration of diabetes between the groups. Fasting C-peptide (P≤0.05) and 2-hour C-peptide 
(P≤0.05) were higher in responders compared to non-responders. Significantly higher C-
peptide levels were observed preoperatively at all time points for responders, with 
significantly higher area under the curve (AUC0-60 and AUC0-120). Using the lower quartiles 
for C-peptide levels, both fasting C-peptide (>2.5ng/mL [0.83nmol/L]) and 2-hour C-peptide 
(>5.2ng/mL [1.73nmol/L]) had a sensitivity and negative predictive value of 100% to predict 
T2DM remission. Logistic regression showed C-peptide, duration of diabetes and BMI were 
associated with response. The area under the ROC curve was 0.94 and a regression model 
predicted diabetes remission with a sensitivity of 85.7% and a specificity of 88.9%. 
Conclusions: This study demonstrated that static (fasting) and dynamic (AUC, 2-hour) C-
peptide measurements predict T2DM resolution 6 months following bariatric surgery. This 
work provides insight into C-peptide dynamics as a predictor of response to bariatric surgery. 
 
Keywords: Type 2 diabetes, C-peptide, Insulin, Bariatric surgery, Area under Curve 
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Abbreviations 
T2DM -Type 2 diabetes mellitus  
%EWL -Percentage of excess weight loss 
HbA1c -Glycated haemoglobin  
OGTT-Oral glucose tolerance test- 
GLP-1-Glucagon-like peptide-1 
IFG-Impaired fasting glycaemia 
IGT-Impaired glucose tolerance 
BMI-Body mass index 
BPD-Bilio-pancreatic diversion 
LSG-Laparoscopic sleeve gastrectomy 
LAGB-Laparoscopic adjustable gastric band 
RYGB-Roux-en-Y gastric bypass 
LDL-C-Low density lipoprotein-cholesterol 
HDL-C-High density lipoprotein-cholesterol 
HOMA-Homeostasis Model Assessment 
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1.1 Introduction 
Bariatric or metabolic surgery has been recommended as an effective treatment option for 
type 2 diabetes mellitus (T2DM) associated with obesity and suboptimal glycaemic control 
despite lifestyle change 
(1)
. While most patients exhibit a significant improvement in T2DM 
following surgery, remission of T2DM is not universal with a proportion of patients showing 
no significant improvement in glycaemic control or recurrence of T2DM at a later stage 
(2-4)
 . 
To date, a definitive clinical and biochemical factor which predicts the resolution of T2DM 
following bariatric surgery has not been identified 
(5)
. Both Pories and Schauer suggested that 
T2DM was more likely to remain postoperatively if the duration of T2DM was greater than 
5-8 years 
(6, 7)
. It has also been observed that the rate of T2DM remission may be related to 
the percentage of excess weight loss (%EWL) achieved post-operatively 
(7-9)
 and that the 
%EWL is predictive of increased insulin sensitivity among subjects with and without T2DM 
(10, 11)
. In addition, subjects with insulin treated T2DM and higher glycated haemoglobin 
(HbA1c) have a reduced likelihood of resolution 
(7)
. Blackstone et al found that both the 
absence of insulin therapy preoperatively and a shorter duration of T2DM independently 
predicted remission 
(12)
.  
 
Total plasma insulin concentrations are in part dependent on the body mass of an individual 
and the degree of insulin resistance within an individual 
(13)
. Since C-peptide is a direct 
measure of insulin production this may provide a more accurate measure of beta-cell insulin 
responsiveness to glucose 
(14-16)
. An important determinant of T2DM remission is circulating 
levels of C-peptide that reflects pancreatic beta-cell reserve 
(17)
. In T2DM, insulin levels may 
be supraphysiological due to a compensatory increase in insulin production associated with 
insulin resistance. However, in the later stages of T2DM, there is associated beta-cell 
dysfunction and failure leading to low insulin and C-peptide levels 
(18, 19)
. Higher C-peptide 
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levels have been described in subjects with remission of T2DM compared to those without 
remission 
(20)
 suggesting that preoperative C-peptide evaluation may have a role in predicting 
the best patients for bariatric surgery. This has also been supported by other studies, but the 
role of C-peptide as a prognostic marker of T2DM remission has not translated to routine 
clinical practice 
(20-22)
. Most of the studies to date have been conducted in Asian samples, a 
group who display variation in the T2DM phenotype (e.g. younger onset of diabetes, lower 
body mass index-BMI) compared to white Caucasian populations. Therefore these studies 
cannot be generalised. A recent publication reported that a fasting C-peptide level >2.9ng/mL 
[0.97nmol/L] provides a useful cut off for predicting the resolution of T2DM with a 
sensitivity of 78% and specificity of 72% in a Chinese sample of subjects 
(23)
. A similar 
finding was noted in a Dutch study where complete resolution of T2DM was observed in 
74% of patients with a preoperative fasting C-peptide levels >3.0 ng/mL (1.0 nmol/L). In 
contrast, none of the T2DM patients with preoperative fasting C-peptide <3.0 ng/mL (1.0 
nmol/L) showed resolution 
(24)
.  
 
Our aim was to perform a focussed detailed study to investigate the predictive value of static 
(fasting) and dynamic C-peptide (2-hour, area under the curve-AUC) measurements during 
an oral glucose tolerance test (OGTT) in relation to resolution of T2DM 6 months after 
bariatric surgery regardless of operation type. From the outset our aim was not to examine 
different surgical techniques on the predictive use of C-peptide, but rather preoperative C-
peptide dynamics in relation to the resolution of T2DM. 
 
1.2 Methods 
1.2.1 Study participants 
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Approval for the study was obtained from the Local Research Ethics Committee (South West 
Wales; LREC reference 06/WMW02/7). Participants were identified and recruited from 
patients undergoing a planned bariatric surgical procedure. Entry criteria at the outset 
included: - both genders, age 20-65 years, body mass index (BMI) >40kg/m
2
 and physically 
fit for surgery. All subjects either had previously diagnosed T2DM, or T2DM diagnosed 
during an oral 75g OGTT 1 month prior to surgery according to ADA criteria at that time 
(25, 
26)
. Participants with pre-existing diabetes treated with diet, oral agents, Glucagon-like 
peptide-1 (GLP-1) analogues or insulin were included. Participants with impaired glucose 
regulation comprising of either impaired fasting glycaemia [IFG] (5.6-6.9mmol/L) or 
impaired glucose tolerance [IGT] (2-hour glucose: 7.8-11.0mmol/L) 
(25)
 were excluded. 
 
1.2.2 Study design 
Participants were recruited prospectively and consecutively from the Bariatric Surgical clinic 
and were not blindly allocated to a surgical treatment option. As per local guidance at the 
time of recruitment, those with a BMI>50kg/m
2
 were routinely offered bilio-pancreatic 
diversion (BPD), whereas those with a BMI below this were usually offered laparoscopic 
sleeve gastrectomy (LSG). LSG was a standard sleeve i.e. sleeve fashioned around a 32F 
bougie taken from 5cm proximal to the pylorus and up to the left crus. BPD involved a distal 
gastrectomy (as described by Scopinaro 
(27)
) and a 50cm common channel. A smaller 
proportion of participants had undergone laparoscopic adjustable gastric band (LAGB) and a 
Roux-en-Y gastric bypass (RYGB). LAGB was performed using the Pars Flaccida technique 
and RYGB by creating a small stomach pouch starting below the second major vessel on the 
lesser curve and 100/100cm alimentary and biliopancreatic limbs. All participants were 
recruited pre-operatively and seen post-operatively at 6 months where they underwent a 
standardized 75g OGTT (122mls of Polycal 61.9g/100ml of glucose, Nutricia Clinical Care, 
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Trowbridge, UK). Previous studies have demonstrated that the level of glycaemia reached 2 
hours after 75g of glucose is closely related to the level of glycaemia after a standardized 
meal indicating an OGTT is a valid tool for revealing altered carbohydrate metabolism during 
a meal 
(28)
. Insulin or oral hypoglycemic agents were omitted the night before the OGTT. 
There was no standardized meal prescribed for the night before and subjects were asked to 
fast from the midnight before the test.  
 
1.2.3 Baseline clinical and biochemical information 
Baseline clinical measurements consisted of weight, height, body mass index (BMI), waist 
circumference, systolic and diastolic blood pressure. Baseline biochemical measurements 
(total cholesterol, low density lipoprotein-cholesterol [LDL-C], high density lipoprotein-
cholesterol [HDL-C] and triglycerides) were analyzed within the local hospital accredited 
laboratory. Glucose (Roche Modular P800 Analyzer) and insulin and C-peptide (Roche E170 
Modular Analyzer) were also measured locally. During the OGTT, plasma and serum 
samples were collected for measurements of glucose, insulin and C-peptide at time 0, 15, 30, 
45, 60 and 120 minutes. All samples were collected on ice, centrifuged and separated within 
one hour of collection and subsequently stored at -80
o
C until analysis.  
 
1.2.4 Measurements of insulin sensitivity 
The Homeostasis Model Assessment (HOMA) was used to estimate steady state beta cell 
function (%B) and insulin sensitivity (%S) preoperatively and postoperatively were 
calculated using the Oxford University on-line calculator 
(http://www.dtu.ox.ac.uk/homacalculator, accessed 7
th
 May 2013) 
(29)
. HOMA-IR is the 
reciprocal of HOMA %S. HOMA %S represent values of 100% in normal young adults when 
using currently available assays for insulin, specific insulin or C-peptide. The accuracy of 
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these measures has been validated and has been shown to correlate with clamp-derived 
indices of insulin sensitivity and secretion 
(30)
. The fasting C-peptide to insulin ratio was 
calculated as an index of hepatic insulin clearance 
(31)
.  
 
1.2.5 Statistical analysis 
A responder at 6 months was defined as a subject with a fasting plasma glucose <5.6mmol/L 
and HbA1c <6.0% at 6 months. This is in line with established criteria for evaluating the 
resolution of diabetes 12 months after bariatric surgery based on fasting glucose and HbA1c 
(32)
. A non-responder was defined as a subject not achieving these criteria. 
Statistical analysis was performed using SPSS (version 22, SPSS Inc., Chicago). Results for 
continuous variables are presented as mean and standard deviation and in graphical 
representation as mean and standard error. Triglyceride did not have a normal distribution 
and underwent log transformation to normalize the data for analysis and is described with the 
geometric mean and approximate standard deviation. Mean differences between responders 
and non-responders were examined using an independent sample t-test for continuous 
variables and by a Chi-squared test for categorical variables. For insulin and C-peptide, the 
mean values at the time points of the OGTT were compared to the time at 0 minutes using a 
paired t-test. Changes in the area under the curve over 30 (AUC0-30), 60 (AUC0-60) and 120 
minutes (AUC0-120) were analyzed during the OGTT preoperatively and 6 months 
postoperatively for glucose, insulin and C-peptide using the trapezoidal rule. In all cases a 
P≤0.05 was considered statistically significant. Correlations were examined using Pearson’s 
correlation. Sensitivity, specificity, positive and negative predictive values were calculated 
for the median and lower quartile cut-off values of fasting and 2-hour C-peptide as predictors 
of diabetes remission. 
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We used a logistic regression model to ascertain the effects of preoperative fasting C-peptide, 
BMI and duration of the diabetes in relation to diabetes outcome 6 months postoperatively. 
This is in line with a previous study by Dixon et al 
(23)
. Diabetes outcome (responder vs non-
responder) was considered as the response variable and fasting C-peptide, BMI and duration 
of the diabetes as the predictors in the binary logistic regression model. We did not include 
the 2-hour C-peptide measurement since it was highly correlated with the fasting C-peptide 
and thus would increase the possibility of multicolinearity which would thereby violate the 
regression model’s assumption. We also calculated sensitivity and specificity and the receiver 
operator characteristic (ROC) curve to check the predictive power of the regression model for 
predicting diabetes remission 6 months following surgery. 
 
1.3 Results 
1.3.1 Participant characteristics 
The sample comprised of 24 white Caucasian subjects with T2DM with a mean age of 49.2 
±6.2 years (range 38-62 years). In line with previous publications, there were significant 
reductions 6 months postoperatively compared to baseline for BMI (55.7 ±12.0 v 44.0 ±9.9 
kg/m
2
, P<0.001), weight (158.3 ±38.9 v 124.8 ±31 kg, P<0.001) and waist circumference 
(145 ±18 v 125 ±19 cm, P<0.001). The mean excess weight loss was 33.5 ±18.9 kg, P<0.001 
with a mean %EWL of 59.7 ±18.0%. Significant improvements were also observed in 2-hour 
plasma glucose (15.4 ±4.3 v 9.1 ±5.5 mmol/L, p<0.001) and HbA1c (7.6 ±1.5 v 6.3 ±1.3%, 
P=0.01). Fasting plasma glucose was not statistically different at 6 months (9.6 ±4.3 v 6.3 
±2.9 mmol/L, P=0.07). No changes were observed in LDL-C, HDL-C and systolic blood 
pressure postoperatively. There was a significant reduction in diastolic blood pressure (79 ±9 
v 73 ±12 mmHg, P=0.02).  
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1.3.2 Responder and non responders 
1.3.2.1 Static measures of glucose and insulin homeostasis 
Within the sample there were 11 responders and 13 non-responders at 6 months including 16 
females and 8 males. Table 1 shows the baseline preoperative measures grouped by responder 
status at 6 months postoperatively. No differences were observed in body mass, fasting and 2-
hour glucose and HbA1c by responder status, however, there was a significant difference 
(P<0.05) in the duration of diabetes between the groups. Fasting C-peptide (P≤0.05) and 2-
hour C-peptide (P≤0.05) were also higher in responders compared to non-responders. Of 
interest the reduction in BMI in the responder compared to the no-responders following 
surgery was not statistically significant (-13.7 ±5.7 v -10.2 ±6.7 kg/m
2
, P=0.19). 
 
1.3.2.2 Dynamic measures of glucose and insulin homeostasis 
No differences were observed in the preoperative AUCs for glucose and insulin by responder 
status. Figure 1 shows C-peptide and insulin values during the preoperative 2-hour OGTT. 
Significantly higher C-peptide levels were observed preoperatively at all the time points for 
responders. This is in keeping with significantly higher AUC0-60 and AUC0-120 for C-peptide 
(Table 2) for responders compared to non-responders.  
 
1.3.2.3 Relationships between C-peptide measurements and duration of diabetes and logistic 
regression analysis 
Fasting C-peptide was correlated with 2-hour C-peptide (r=0.81, P<0.001) and AUC0-60 
(r=0.95, P<0.001) and AUC0-120 (r=0.90, P=0.001). In addition 2-hour C-peptide was 
correlated with AUC0-60 (r=0.89, P<0.001) and AUC0-120 (r=0.96, P=0.001). No correlation 
was observed between duration of diabetes and fasting C-peptide (r=-0.08, P=0.77), 2-hour 
C-peptide (r=-0.24, P=0.37), AUC0-60 (r=-0.20, P=0.45) and AUC0-120 (r=-025, P=0.35).  
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The results of the logistic regression model showed a good fit to the data according to the 
Hosmer and Lemeshow goodness of fit test (the Chi-square test statistics is not significant as 
P>0.05). The model explained 65.5% of the diabetes remission (Nagelkerke R
2
) 6 months 
postoperatively. The overall predictive accuracy was 87.5% according to the classification 
table of the logistic regression model. However, even though the model was significant, none 
of the predictors were statistically significant. This is likely to be because of the small size 
and the existence of missing values. The equation of the regression model was as follows:-   
In(odds) = 4.1 – 0.154 (BMI) + 1.4 (fasting C-peptide) – 0.028 (duration of diabetes) 
It is evident from the regression equation that both BMI and duration of diabetes have a 
negative effect on diabetes remission after 6 months (i.e. higher the preoperative BMI and/or 
duration of diabetes, the less likely to have the remission after the surgery). In contrary, 
fasting C-peptide was found to have a positive effect and was the biggest predictor (highest 
odds ratio in the model) of diabetes remission. The area under the ROC curve was 0.94 which 
suggests that the logistic regression model is robust in differentiating between a responder 
and non-responder at follow-up. The coordinates of the ROC curve are shown in Figure 2 
along with the coordinates table (Table 3). These show that the regression model predicts the 
remission of diabetes with a sensitivity of 85.7% and a specificity of 88.9%. 
 
1.3.2.4 Preoperative quartiles of static and dynamic C-peptide and  diabetes resolution 
Figure 3 shows the percentage of responders grouped by quartiles of fasting C-peptide, 2-
hour C-peptide and AUC0-120 for C-peptide. No responders were seen in the lowest quartile 
for all of these measures. A linear association was observed for C-peptide AUC0-120 across 
groups. Table 4 shows the sensitivity, specificity, positive and negative predictive values for 
predicting a responder. These are discrete calculations and are displayed taking the lower 
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quartile value and the median values for each fasting C-peptide and 2-hour C-peptide. Using 
the lower quartile cut-off, both fasting C-peptide and 2-hour C-peptide had a sensitivity and 
negative predictive value of 100%. Using the median values the sensitivity and negative 
predictive values were approximately 70% and 60% respectively for both measures. 
 
1.4 Discussion 
This small but focused study shows that preoperative static and dynamic C-peptide 
measurements aid in the prediction of T2DM resolution 6 months following bariatric surgery. 
To our knowledge, no previous studies have examined preoperative AUCs for C-peptide in 
relation to T2DM resolution postoperatively. This examination of AUC is thus novel and 
worthy of reporting. We observed that fasting C-peptide was an independent predictor of 
T2DM resolution at 6 months. Of interest, a previous study by Dixon and colleagues 
(23)
 
within a Chinese sample observed that a fasting C-peptide >2.9ng/mL (0.97nmol/L) provided 
predictive accuracy in predicting diabetes resolution. Aarts et al also observed similar cut-off 
level of fasting C-peptide 3ng/ml [>1nmo/L] in predicting T2DM resolution. We observed 
that no responders had a fasting C-peptide <2.5ng/mL (0.83nmol/L) (our lower quartile). We 
also observed that the duration of diabetes, static 2-hour C-peptide, AUC0-60 and AUC0-120 
were different between responders and non-responders. These observations re-affirm the role 
of C-peptide as a prognostic marker. Of note, we observed that duration of diabetes was not 
correlated with any of the C-peptide markers, suggesting that caution may be required if 
duration of diabetes is to be used as an exclusive prognostic marker of T2DM resolution. 
Logistic regression showed C-peptide, duration of diabetes and BMI were associated with 
response. The area under the ROC curve was 0.94 and a regression model predicted diabetes 
remission with a sensitivity of 85.7% and a specificity of 88.9%. This is in line with the 
previous study by Dixon et al in a Chinese sample of subjects
(23)
. 
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Previously, low levels of C-peptide have been of use in identifying patients at risk of diabetes 
or with insulin deficiency such as type 1 diabetes and latent autoimmune diabetes in adults 
(33, 
34)
. Fasting C-peptide is a relatively simple test to perform and may therefore form an easy 
and accurate measure, which may aid in predicting the resolution of T2DM postoperatively 
and the need for potential T2DM related treatments postoperatively at 6 months. In addition 
the measurement of a 2-hour C-peptide also aids as a predictive method. Whilst the 
measurement of the AUC for C-peptide may not be practical as a routine test, our study 
shows good correlation between this the static measurements of C-peptide. Within our 
current study we did not examine the effects of C-peptide as a predictor of T2DM resolution 
in relation to different bariatric operations. Our aim was to examine the C-peptide 
measurements as predictors of response in a bariatric sample of subjects. Clearly different 
bariatric procedures are associated with different outcomes in relation to T2DM, however 
there is a growing body of evidence suggesting that LSG, BPD and RYGB may have a 
similar efficacy in the resolution of T2DM 
(26, 35)
. Strengths of the current study include the 
well-detailed static and dynamic measurements performed within the white-Caucasian 
sample of subjects with T2DM. The main limitation of our study was the small number of 
patients included. Further studies are required with subjects from different cultural 
backgrounds after stratifying by types of surgery, and we would also suggest that such a 
study re-examines the subjects for longer periods post-operatively (e.g. 12 months and 
beyond). 
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Table and Figure legends 
Table 1: Baseline characteristics of participants 
LAGB: Laparoscopic adjustable gastric band; LSG: Laparoscopic sleeve gastrectomy; BPD: 
Biliopancreatic diversion; RYGB: Laparoscopic Roux-en-Y Gastric Bypass. 
*
Geometric mean and approximate standard deviation shown for log-transformed data. 
 
Table 2: Preoperative AUCs for glucose, insulin and C-peptide in responders and non 
responders at 6 months 
AUC: Area under the curve for 0-30, 0-60 and 0-120 minutes. 
 
Table 3: Coordinates of the ROC Curve from logistic regression 
*
The smallest cut-off value is the minimum observed test value minus 1, and the largest cut-
off value is the maximum observed test value plus 1. All the other cut-off values are the 
averages of two consecutive ordered observed test values. We observed from the results of 
the coordinates table that the regression model predicts the remission of diabetics with a 
sensitivity of 85.7% and a specificity of 88.9%. 
 
Table 4: Sensitivity, specificity, positive and negative predictive values of C-peptide 
measurements for resolution of T2DM 
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*
Median value; 
†
Lower quartile cut off. 
PPV: Positive predictive value; NPV: Negative predictive value. 
95% confidence intervals shown. 
*
Median value; 
†
Lower quartile cut off. 
PPV: Positive predictive value; NPV: Negative predictive value. 
95% confidence intervals shown. 
 
Figure 1: ROC curve using BMI, duration of diabetes and fasting C-peptide for 
predicting diabetes remission 6 months following surgery 
The area under the ROC curve is 0.94. 
 
Figure 2: C-peptide and insulin measurements during the 2 hour oral glucose tolerance 
test preoperatively in relation to responders and non responders at 6 months 
Mean and standard error is shown. 
*P≤0.05.  
Figure 2a: C-peptide. Significant differences in C-peptide were observed at all time points 
apart from 15 minutes between responders and non-responders at 6 months.  
Figure 2b: Insulin. No differences were seen with respect to insulin at any time points 
between responders and no responders. 
 
Figure 3: Percentage of responders grouped by preoperative quartiles of fasting C-
peptide, 2-hour C-peptide and AUC0-120 for C-peptide  
Figure 3a: Fasting C-peptide. No responders were observed to be in the lowest quartile of 
fasting C-peptide (≤2.5ng/mL). Chi-squared analysis of the differences between the four 
groups revealed a significant difference (P=0.03). 
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Figure 3b: 2-hour C-peptide. No responders were observed to be in the lowest quartile of 2-
hour C-peptide (≤5.2ng/mL). Chi-squared analysis of the differences between the four groups 
revealed was not significant (P=0.07). 
 
Figure 3c: AUC0-120. No responders were observed to be in the lowest quartile of 2-hour C-
peptide (≤7.7281 ng h mL-1). Chi-squared analysis of the differences between the four groups 
revealed was not significant (P=0.07), but a significant linear association was observed across 
groups (P=0.03).  
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Tables 
Table 1: Baseline preoperative characteristics of participants 
Measurement Responder 
(n=11) 
Non responder 
(n=13) 
P  
Age (years) 47.5 (7.6) 50.7 (6.2) 0.26 
Gender (F/M) 8/3 8/5 0.68 
 Operation 
(LAGB, LSG, BPD, RYGB) 
0/6/4/1 2/3/6/2 0.31 
Duration of diabetes (months) 39 (30) 91 (57) 0.03 
Weight (kg) 153.7 (44.9) 162.2 (32.5) 0.60 
BMI (kg/m
2
) 52.6 (10.0) 58.4 (13.3) 0.25 
Waist (cm) 142 (23) 151 (19) 0.29 
Excess weight (kg) 81.4 (37.6) 92.5 (32.1) 0.45 
% Excess weight 50.9 (9.5) 55.6 (8.7) 0.22 
Systolic BP (mmHg) 130 (110) 140 (21) 0.16 
Diastolic BP (mmHg) 75 (10) 83 (7) 0.03 
LDL-C (mmol/L) 2.4 (0.9) 2.0 (0.6) 0.16 
HDL-C (mmol/L) 1.1 (0.3) 1.1 (0.3) 0.81 
Triglyceride (mmol/L)
*
 2.8 (1.3) 1.7 (0.4) 0.18 
HbA1c (%) 
HbA1c (mmol/mol)                       
7.8 (1.8) 
62 (19.7) 
8.0 (1.3) 
64 (14.2) 
0.77 
0.77 
Fasting glucose (mmol/L) 9.6 (5.0) 9.6 (3.8) 0.97 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
2-hour glucose (mmol/L) 14.9 (4.7) 15.9 (4.1) 0.59 
Fasting insulin (IU/mL) 31.2 (17.4) 31.2 (14.4) 1.00 
2-hr insulin (IU/mL) 116.38 (88.87) 69.91 (71.09) 0.21 
Fasting C-peptide (ng/mL) 4.9 (1.9) 3.3 (1.8) 0.05 
2-hr C-peptide (ng/mL) 12.1 (6.0) 7.0 (4.9) 0.05 
HOMA B 42.2 (27.7) 29.3 (17.2) 0.26 
HOMA %S 261.7 (123.6) 256.8 (226.2) 0.96 
HOMA- IR 0.438 (0.177) 0.680 (0.505) 0.22 
C-pep: Insulin ratio 0.221 (0.075) 0.148 (0.124) 0.15 
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Table 2: Preoperative AUCs for glucose, insulin and C-peptide in 
responders and non responders at 6 months 
 Responder Non responder P 
AUC0-30 
Glucose (mmol h L
-1
) 5.3 (3.0) 4.5 (1.1) 0.47 
Insulin (IU h mL
-1
)
 
 25.5 (15.6) 20.1 (16.0) 0.47 
C-peptide (ng h mL
-1
) 3.2 (1.3) 2.0 (1.2) 0.06 
AUC0-60 
Glucose (mmol h L
-1
) 13.0 (5.5) 11.2 (2.9) 0.39 
Insulin (IU h mL
-1
)
 
 73.0 (40.7) 50.5 (37.4) 0.23 
C-peptide (ng h mL
-1
)
 
 7.8 (3.1) 4.6 (2.7) 0.03 
AUC0-120 
Glucose (mmol h L
-1
) 28.8 (10.3) 25.2 (6.0) 0.38 
Insulin (IU h mL
-1
)
 
 186.0 (114.0) 122.8 (87.2) 0.19 
C-peptide (ng h mL
-1
)
 
 19.2 (8.2) 10.9 (6.2) 0.02 
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Table 3: Coordinates of the ROC Curve from logistic regression 
Positive if Greater 
Than or Equal To
*
 
Sensitivity 1 - Specificity 
.0000000 1.000 1.000 
.0012721 1.000 .889 
.0083456 1.000 .778 
.0191814 1.000 .667 
.0744818 1.000 .556 
.1862974 1.000 .444 
.2616588 1.000 .333 
.2860215 1.000 .222 
.3145491 .857 .222 
.4411510 .857 .111 
.5503349 .714 .111 
.6875347 .571 .111 
.8352490 .571 .000 
.8850525 .429 .000 
.9561757 .286 .000 
.9934894 .143 .000 
1.0000000 .000 .000 
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Table 4: Sensitivity, specificity, positive and negative predictive values of 
C-peptide measurements for resolution of T2DM 
 Sensitivity Specificity PPV NPV 
Fasting C-peptide 
>4.25 ng/mL
*
 67.7% 
(29.9-92.5%) 
63.6% 
(30.8-89.1%) 
64.3% 
(35.1-87.2%) 
100.0% 
(54.0-100%) 
>2.5 ng/mL
†
 
 
100% 
(66.4-100%) 
54.6% 
(23.4-83.3%) 
100% 
(54.1-100%) 
64.3% 
(35.2-87.1%) 
2-hour C-peptide 
>8.5 ng/mL
*
 70.0%  
(34.8-93.3%) 
63.4% 
(30.8-89.1%) 
63.6% 
(30.8-89.1%) 
70.0% 
34.8-93.3%) 
>5.2 ng/mL
†
 100% 
(63.1-100%) 
45.5% 
(16.8-76.6%) 
42.1% 
(20.3-66.5%) 
100% 
(47.8-100%) 
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Figure 1A 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
Figure 1B 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
 
Figure 2 
Li
ne
 o
f u
ni
ty
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
 
Figure 3A 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
28 
 
Figure 3B 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
29 
 
Figure 3C 
 
